Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00514
|
|||||
Drug Name |
Darunavir
|
|||||
Synonyms |
(3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; AIDS073035; Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; Darunavir (USAN/INN); Darunavir [USAN]; Darunavirum; Darunavirum [INN-Latin]; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide; Prezista; Prezista(TM); TMC 114; TMC-114; TMC114; UIC 94017; UIC-94017; UIC-96017; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Human immunodeficiency virus infection [ICD11: 1C62.Z] | Approved | [1] | |||
Therapeutic Class |
Antiviral Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C27H37N3O7S
|
|||||
Canonical SMILES |
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N
|
|||||
InChI |
InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1
|
|||||
InChIKey |
CJBJHOAVZSMMDJ-HEXNFIEUSA-N
|
|||||
CAS Number |
CAS 206361-99-1
|
|||||
Pharmaceutical Properties | Molecular Weight | 547.7 | Topological Polar Surface Area | 149 | ||
Heavy Atom Count | 38 | Rotatable Bond Count | 12 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 9 | |||
XLogP |
2.9
|
|||||
PubChem CID | ||||||
PubChem SID |
10322685
, 10322696
, 104223585
, 104234207
, 11108879
, 113453152
, 115001517
, 117695824
, 12015589
, 14719987
, 14719990
, 14720157
, 14788134
, 17397753
, 30417278
, 46394098
, 46394099
, 46394100
, 46394252
, 46394253
, 46394275
, 46394276
, 46506908
, 49661683
, 49743126
, 49743141
, 49743143
, 50070565
, 50071308
, 50074527
, 50113275
, 50333303
, 53777066
, 57399654
, 628316
, 7884953
, 85098698
, 85177032
, 85177058
, 85756739
, 85756740
, 87351130
, 87557585
, 87557699
, 87557709
, 87557710
, 9371109
, 99226867
, 99226870
, 99226871
|
|||||
ChEBI ID |
CHEBI:367163
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [2] | |
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
References | ||||||
1 | Darunavir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 2009 Sep;32(9):1588-93. | |||||
3 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. | |||||
4 | Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother. 2010 Nov;65(11):2319-28. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.